- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Goldman Sachs Bets Large on Biocon Biosimilars
Biocon Biologics nets a $150 million investment from Goldman Sachs to further its development and marketing of biosimilars.
Biosimilar company Biocon Biologics said it will receive a $150 million investment from Goldman Sachs.
Biocon said in a statement that it regarded the capital infusion as a sign of confidence from the global investment community in the potential of the Bangalore, India-based company.
“This capital injection by Goldman Sachs will enable us to make prudent investments in [research and development], high-quality manufacturing, as well as establish a global commercial footprint,” said Christiane Hamacher, PhD, CEO of Biocon Biologics.
Biocon markets 2 biosimilars in the US: a trastuzumab (Ogivri) and a pegfilgrastim (Fulphila), both in partnership with Mylan. The companies have also launched an insulin glargine (Semglee), which references Lantus.
The product is essentially a biosimilar, but was not approved as one owing to the regulatory pathway followed. Biocon and Mylan are seeking biosimilar and interchangeable status for Semglee. Interchangeable status would mean pharmacists could dispense it without physician involvement.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
